Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

Haematologica

Volumn 93, Issue 5, 2008, Pages 775-779

  Falini, Brunangelo ^a   Martelli, Maria Paola ^a   Mecucci, Cristina ^a   Liso, Arcangelo ^b   Bolli, Niccolò ^a   Bigerna, Barbara ^a   Pucciarini, Alessandra ^a   Pileri, Stefano ^c   Meloni, Giovanna ^d   Martelli, Massimo F ^a   Haferlach, Torsten ^e   Schnittger, Susanne ^e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute myeloid leukemia; Antibodies; Immunohistochemistry; Mutations; NPM; Nucleophosmin

Indexed keywords

NUCLEOPHOSMIN; NUCLEOPHOSMIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; SEVERE COMBINED IMMUNODEFICIENCY; XENOTRANSPLANTATION;

ADULT; ANIMALS; CHROMOSOME ABERRATIONS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; RECURRENCE;

EID: 43449096376     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12225     Document Type: Article

References (25)

1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
2. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006;107:4514-23.
3. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007;109:874-85.
4. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007;92: 519-32.
5. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005; 106:899-902.
6. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008;105:3945-50.
7. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106: 2854-61.
8. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006;66:3310-6.
9. Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 2007;92: 1268-9.
10. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108:1999-2005.
11. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106: 3733-9.
12. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760-7.
13. Bolli N, Galimberti S, Martelli MP, Tabarrini A, Roti G, Mecucci C, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 2006;7:350-2.
14. Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 1989;3:264-9.
15. Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007;21:2000-9.
16. Falini B, Mecucci C, Saglio G, Lo Coco F, Brown P, Diverio D, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis on 2,562 AML patients. Haematologica 2008; 93:439-42.
17. Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007; 67:6230-7.
18. Mariano AR, Colombo E, Luzi L, Martinelli P, Volorio S, Bernard L, et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene 2006;25:4376-80.
19. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 2007;21:1099-103.
20. Pitiot AS, Santamaria I, Garcia-Suarez O, Centeno I, Astudillo A, Rayon C, et al. A new type of NPM1 gene mutation in AML leading to a C-terminal truncated protein. Leukemia 2007;21:1564-6.
21. Falini B, Albiero E, Bolli N, De Marco MF, Madeo D, Martelli M, et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia 2007;21:2052-4.
22. Liso A, Bogliolo A, Freschi V, Martelli M, Pileri A, Santodirocco M, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nuclephosmin (NPM1) mutations and is restricted to AML. Leukemia 2007;[Epub ahead of print].
23. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103-8.
24. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007;21:998-1004.
25. Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, Colombo E, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999;93:632-42.